Reviews:
Soluble fibrinogen like protein 2 sFGL2 the novel effector molecule for immunoregulation
PDF | Full Text | How to cite
Metrics: PDF 3943 views | Full Text 5862 views
Xin-guang Liu1,*, Yu Liu2,* and Feng Chen1,3
1 Department of Hematology, Qilu Hospital, Shandong University, Jinan, P. R. China
2 School of Chemistry and Pharmaceutical Engineering, Qilu University of Technology, Jinan, P. R. China
3 Capital Medical University Cancer Center, Beijing Shijitan Hospital, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Beijing, China
* These authors have contributed equally to this paper
Correspondence to:
Feng Chen, email:
Keywords: soluble fibrinogen-like protein 2; immunoregulation; transplantation; hepatitis; autoimmunity
Received: July 25, 2016 Accepted: September 29, 2016 Published: October 08, 2016
Abstract
Soluble fibrinogen-like protein 2 (sFGL2) is the soluble form of fibrinogen-like protein 2 belonging to the fibrinogen-related protein superfamily. It is now well characterized that sFGL2 is mainly secreted by regulatory T cell (Treg) populations, and exerts potently immunosuppressive activities. By repressing not only the differentiation and proliferation of T cells but also the maturation of dendritic cells (DCs), sFGL2 acts largely as an immunosuppressant. Moreover, sFGL2 also induces apoptosis of B cells, tubular epithelial cells (TECs), sinusoidal endothelial cells (SECs), and hepatocytes. This mini-review focuses primarily on the recent literature with respect to the signaling mechanism of sFGL2 in immunomodulation, and discusses the clinical implications of sFGL2 in transplantation, hepatitis, autoimmunity, and tumors.